Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation
of B lymphocytes, which may result in many adverse consequences and even death if not treated
actively. Telitacicept, approved conditionally in China in March 2021, is a biologic agent
targeting B lymphocyte stimulator (BLyS）and a proliferating inducing ligand (APRIL) dually
for patients with active SLE patients who have not responded to conventional treatment. The
investigators hope to screen predictive biomarkers of efficacy and explore the mechanism of
difference in efficacy of Telitacicept with Chinese characteristics by omics.